MAP3K12 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-MAP3K12 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | MAP3K12 |
| Clone | [473CT23.12.5] |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | ammonium sulfate precipitate |
| Size | 0.2 mL |
| Concentration | 2.12mg/ml |
| Applications | ELISA (EL/EIA), Western Blot (WB) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: Human MAP3K12. This gene encodes a member of the serine/threonine protein kinase family. This kinase contains a leucine-zipper domain and is predominately expressed in neuronal cells. The phosphorylation state of this kinase in synaptic terminals was shown to be regulated by membrane depolarization via calcineurin. This kinase forms heterodimers with leucine zipper containing transcription factors, such as cAMP responsive element binding protein (CREB) and MYC, and thus may play a regulatory role in PKA or retinoic acid induced neuronal differentiation. Alternatively spliced transcript variants encoding different proteins have been described.[provided by RefSeq]. |
| Immunogen | Immunogen: KLH-conjugated synthetic peptide mapping to a fragment of residue within amino acids 828-859 of human MAP3K12. |
| Other Names | MAP3K12 (MAP3K12, ZPK, Mitogen-activated protein kinase kinase kinase 12, Dual leucine zipper bearing kinase, Leucine-zipper protein kinase, MAPK-upstream kinase, Mixed lineage kinase) |
| Gene, Accession # | Gene ID: 7786, NCBI: AAH50050.1, UniProt: Q12852 |
| Catalog # | MBS645852 |
| Price | $610 |
| Order / More Info | MAP3K12 Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies